A Study of SEA-CD40 Given With Other Drugs in Cancers

Official Title

An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies

Summary:

This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug.

There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.

Trial Description

Primary Outcome:

  • Confirmed Objective Response Rate (ORR)
Secondary Outcome:
  • Incidence of adverse events (AEs)
  • Incidence of laboratory abnormalities
  • Incidence of dose alterations
  • Disease control rate (DCR) per investigator assessment
  • Duration of response (DOR) per investigator assessment
  • Progression-free survival (PFS) per investigator assessment
  • Overall survival (OS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society